Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Appointed director
Acq. announced
Quarterly results
Director departure
ChromaDex Corp. (CDXC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Investor presentation, Quarterly results
Docs: "ChromaDex Corporation Reports Second Quarter 2023 Financial Results",
"SAFE HARBOR STATEMENT SAFE HARBOR STATEMENT 2"
03/08/2023 8-K Investor presentation
Docs: "ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results",
"ChromaDex Earnings Conference Call Fourth Quarter 2022 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific"
08/10/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/23/2022 8-K Investor presentation
Docs: "Investor Presentation Rob Fried Chief Executive Officer Kevin Farr Chief Financial Officer Nasdaq: CDXC"
03/09/2022 8-K Quarterly results
11/03/2021 8-K Investor presentation, Quarterly results
Docs: "ChromaDex Corporation Reports Third Quarter 2021 Financial Results",
"ChromaDex Earnings Conference Call Third Quarter 2021 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder"
08/03/2021 8-K Investor presentation, Quarterly results
Docs: "ChromaDex Corporation Reports Second Quarter 2021 Financial Results",
"0 200 400 600 800 1000 1200 1400 1600 2013 2014 2015 2016 2017 2018 2019 2020 2021 C"
05/06/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
12/09/2020 8-K Investor presentation
Docs: "PRESENTATION"
11/04/2020 8-K Investor presentation, Quarterly results
Docs: "Sep. 30, 2019 Sales, net $14,180 $12,053 Cost of sales 5,726 5,304 Gross profit 8,454 6,749 Operating expenses: Sales and marketing 5,223 4,626 Research and development 880 1,044 General and administrative 6,547 7,967 Operating expenses 12,650 13,637 Operating loss Nonoperating expense: Interest expense, net Nonoperating expense Net loss $ $ Basic and diluted loss per common share $ $ Basic and diluted weighted average common shares outstanding 61,695 57,658 See Notes to Consolidated Financial Statements in Part I of ChromaDex's Quarterly Report on Form 10-Q filed with Securities and Exchange Commission on November 4, 2020.",
"PRESENTATION"
08/06/2020 8-K Quarterly results
05/29/2020 8-K Investor presentation
Docs: "Investor Presentation of ChromaDex Corporation"
05/11/2020 8-K Quarterly results
03/10/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/07/2019 8-K Quarterly results
05/09/2019 8-K Investor presentation, Quarterly results
Docs: "Mar. 31, 2018 Sales, net $10,048 $6,567 Cost of sales 4,747 3,430 Gross profit 5,301 3,137 Operating expenses: Sales and marketing 4,174 3,269 Research and development 1,168 1,439 General and administrative 8,331 6,828 Operating expenses 13,673 11,536 Operating loss Nonoperating income : Interest income , net 35 Nonoperating income : 35 Net loss $ $ Basic and diluted loss per common share $ $ Basic and diluted weighted average common shares outstanding 55,325 54,858 See Notes to Condensed Consolidated Financial Statements in Part I of ChromaDex's Quarterly Report on Form 10-Q filed with Securities and Exchange Commission on May 9, 2019. ChromaDex Corporation and Subsidiaries Condensed Consolidated Balance Sheets March 31, 2019 and December 31, 2018 Mar. 31, 2019 Dec. 31, 2018 Assets Curre...",
"Investor Presentation of ChromaDex Corporation"
04/08/2019 8-K Investor presentation
Docs: "Presentation, Investor Frequently Asked Questions"
03/11/2019 8-K Investor presentation
Docs: "Investor Presentation of ChromaDex Corporation"
03/07/2019 8-K Investor presentation
Docs: "CHROMADEX CORPORATION REPORTS 2018 FINANCIAL RESULTS - Full Year 2018 Net Revenues Increased by 49% to $31.6 Million and Fourth Quarter 2018 Net Revenues Increased by 20% to $9.1 Million - Fourth Quarter 2018 Highlights vs. Fourth Quarter 2017 ● Entered into a global license and supply agreement with Nestlé Health Science , which provides NHSc with the exclusive right to include TRU NIAGEN® in its branded medical nutrition products and co-exclusive rights to include TRU NIAGEN in its protein based ready to drink or loose powder beverages; ● Received regulatory approval to sell TRU NIAGEN across all channels in Canada, with initial launch on www.truniagen.ca and to healthcare practitioners at Fullscript Canada; and ● Net sales for the fourth quarter of 2018 we...",
"Investor Presentation of ChromaDex Corporation"
12/04/2018 8-K Investor presentation
Docs: "Investor Presentation of ChromaDex Corporation"
12/04/2018 8-K Investor presentation
Docs: "Presentation, Investor Frequently Asked Questions"
11/07/2018 8-K Investor presentation, Quarterly results
Docs: "Sep. 30, 2017 Sales, net $8,120 $6,084 Cost of sales 3,759 3,169 Gross profit 4,361 2,915 Operating expenses: Sales and marketing 4,837 1,103 Research and development 1,350 1,040 General and administrative 6,770 3,948 Operating expenses 12,957 6,091 Operating loss Nonoperating expense: Interest expense, net Nonoperating expenses Loss from continuing operations Loss from discontinued operations - Gain on sale of discontinued operations - 5,467 Income from discontinued operations - 5,358 Net income $ $2,137 Basic earnings per common share: Loss from continuing operations $ $ Earnings from discontinued operations $- $0.12 Basic earnings per common share $ $0.05 Diluted earnings per common share: Loss from continuing operations $ $ Earnings from discontinued operations $- $0.11 Diluted ear...",
"Investor Presentation of ChromaDex Corporation"
05/10/2018 8-K Investor presentation, Quarterly results
Docs: "ChromaDex Corporation and Subsidiaries Condensed Consolidated Statements of Operations Three Month Periods Ended March 31, 2018 and April 1, 2017 Q1 2017 Sales, net $6,567 $3,368 Cost of sales 3,430 1,750 Gross profit 3,137 1,618 Operating expenses: Sales and marketing 3,269 405 Research and development 1,439 664 General and administrative 6,828 2,322 Operating expenses 11,536 3,391 Operating loss Nonoperating expense: Interest expense, net Nonoperating expenses Loss from continuing operations Loss from discontinued operations - Net loss $ $ Basic and diluted loss per common share: Loss from continuing operations $ $ Loss from discontinued operations $- $ Basic and diluted loss per common share $ $ Basic and diluted weighted average common shares outstanding 54,858 38,031 See Notes to ...",
"INVESTOR PRESENTATION"
04/18/2017 8-K Form 8-K - Current report
12/04/2013 8-K Investor presentation
Docs: "Presentation"
05/29/2013 8-K Investor presentation
Docs: "ChromaDex Corporation Presentation"
06/14/2011 8-K Investor presentation
Docs: "Investor Presentation Slides"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy